
By Sharnita Midgett
As biomarkers have taken on a larger role in the diagnosis of Alzheimer’s disease, even before the onset of symptoms such as cognitive decline, researchers have debated how to label these “pre-clinical” patients.
The evolution of diagnosis also creates a new role for the loved ones of these patients, those who may someday need to care for a patient living with dementia. This, argued two Penn Memory Center (PMC) researchers, is “the dawn of the pre-caregiver.”
In a March 2019 JAMA Neurology article, PMC Co-Director Jason Karlawish, MD, and PMC Scholar Emily Largent, PhD, JD, RN, discussed how the pre-clinical diagnosis of Alzheimer’s disease, in conjunction with new laws, will lead to earlier engagement of family members in care.